FibroGen, Inc (NASDAQ:FGEN)‘s stock had its “buy” rating reissued by analysts at Stifel Nicolaus in a research note issued on Thursday. They presently have a $80.00 price objective on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 55.04% from the company’s current price.

Several other research firms have also commented on FGEN. Citigroup Inc. reiterated a “buy” rating and set a $48.00 price target on shares of FibroGen in a report on Monday, June 26th. Jefferies Group LLC reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a report on Tuesday. Leerink Swann reiterated an “outperform” rating and set a $82.00 price target (up previously from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. BidaskClub raised FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Finally, Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a research report on Friday, July 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $60.17.

Shares of FibroGen (NASDAQ FGEN) traded up 1.793% during midday trading on Thursday, reaching $52.525. 400,118 shares of the company traded hands. The stock has a 50 day moving average price of $41.83 and a 200 day moving average price of $31.58. The firm’s market capitalization is $3.74 billion. FibroGen has a 1-year low of $15.60 and a 1-year high of $52.70.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The company had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million. Analysts expect that FibroGen will post ($1.80) earnings per share for the current fiscal year.

WARNING: “FibroGen, Inc (FGEN) Earns “Buy” Rating from Stifel Nicolaus” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/fibrogen-inc-fgen-earns-buy-rating-from-stifel-nicolaus.html.

In other FibroGen news, VP Pat Cotroneo sold 2,851 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $49.45, for a total value of $140,981.95. Following the completion of the sale, the vice president now owns 157,405 shares in the company, valued at $7,783,677.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $31.52, for a total value of $1,217,806.72. Following the completion of the sale, the chief executive officer now owns 3,330,780 shares of the company’s stock, valued at approximately $104,986,185.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 462,577 shares of company stock valued at $18,446,712. 14.90% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its holdings in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 696 shares during the period. California State Teachers Retirement System grew its holdings in FibroGen by 2.1% during the second quarter. California State Teachers Retirement System now owns 105,288 shares of the biopharmaceutical company’s stock worth $3,401,000 after acquiring an additional 2,180 shares during the period. The Manufacturers Life Insurance Company grew its holdings in FibroGen by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 46,284 shares of the biopharmaceutical company’s stock worth $1,495,000 after acquiring an additional 5,022 shares during the period. Cubist Systematic Strategies LLC acquired a new position in FibroGen during the second quarter worth $348,000. Finally, EcoR1 Capital LLC grew its holdings in FibroGen by 3,674.1% during the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock worth $51,210,000 after acquiring an additional 1,543,448 shares during the period. 47.49% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.